Stocks of Protagonist Therapeutics Inc (NASDAQ:PTGX) traded higher last session on Wall Street, down -0.03% to $38.67.
PTGX stock price is now -0.53% away from the 50-day moving average and -0.77% away from the 200-day moving average. The market capitalization of the company currently stands at $2.30B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $47, Goldman recently initiated with Neutral rating for Protagonist Therapeutics Inc (NASDAQ: PTGX). On December 06, 2024, BMO Capital Markets recently initiated its ‘Outperform’ rating on the stock quoting a target price of $62, while ‘Wedbush’ rates the stock as ‘Outperform’
In other news, MOLINA ARTURO MD, Chief Medical Officer sold 26,000 shares of the company’s stock on Nov 27 ’24. The stock was sold for $1,162,280 at an average price of $44.70. Upon completion of the transaction, the Chief Medical Officer now directly owns 46,444 shares in the company, valued at $1.8 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 26 ’24, Chief Medical Officer MOLINA ARTURO MD sold 5,529 shares of the business’s stock. A total of $252,122 was realized by selling the stock at an average price of $45.60. This leaves the insider owning 46,444 shares of the company worth $1.8 million. A total of 5.86% of the company’s stock is owned by insiders.
During the past 12 months, Protagonist Therapeutics Inc has had a low of $24.22 and a high of $48.89. As of last week, the company has a debt-to-equity ratio of 0.02, a current ratio of 10.70, and a quick ratio of 10.70. According to the stock market information, the enterprise value for the company is $1846834304, which is based on a 14.51 price-to-earnings ratio, a 1.11 price-to-earnings-growth ratio, and a beta of 2.33. The fifty day moving average price for PTGX is $38.8774 and a two-hundred day moving average price translates $38.9695 for the stock.
The latest earnings results from Protagonist Therapeutics Inc (NASDAQ: PTGX) was released for 2024-09-30. The net profit margin was 52.76% and return on equity was 40.97% for PTGX.
